Videos

A Case of Estrogen-Driven Metastatic Breast Cancer

Ajai Chari, MD, discusses the rationale for using combination therapy in patients with multiple myeloma. 

Lori J. Wirth, MD, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.

Alexander E. Perl, MD, discusses the use of antibody-drug conjugates in acute myeloid leukemia. Gemtuzumab ozogamicin has already been approved for this patient population.

Jonathon B. Cohen, MD, discusses the biggest challenge in treating mantle cell lymphoma and how these challenges can be overcome.

Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of thoracic medical oncology in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, discusses the data that were presented at the World Conference on Lung Cancer earlier this year for the IMpower 132 trial comparing the combination of carboplatin/cisplatin plus atezolizumab (Tecentriq) to standard chemotherapy in patients with non–small cell lung cancer.

Danny Rischin, MD, MBBS, FRACP, discusses an ongoing phase III trial for patients with metastatic cutaneous squamous cell carcinoma or recurrent disease after progressing on frontline chemotherapy. 

Julie M. Vose, MD, MBA, discusses the importance of conducting genetic testing on all patients with diffuse large B-cell lymphoma to better understand their disease and treat the disease properly.

Arjun V. Balar, MD, discusses some combinations currently being investigated in clinical trials for patients with bladder cancer.

Hussein A. Tawbi, MD, PhD, discusses why melanoma responds so well to immunotherapy.

During the 2018 Annual Meeting of the Connective Tissue Oncology Society, Anette Duensing, MD, assistant professor of pathology at University of Pittsburgh, discusses the need for further investigation into how treatment type impacts perceived cognitive function in patients with gastrointestinal stromal tumor.

Susan M. O’Brien, MD, discusses the challenges with the 3 oral agents approved in chronic lymphocytic leukemia.

During the 2018 Annual Meeting of the Connective Tissue Oncology Society,&nbsp;Jason Roszik, PhD, MBA, of the MD Anderson Cancer Center, discusses the use of next-generation sequencing in intimal sarcoma.<br /> &nbsp;

During the 2018 Association of Community Cancer Centers National Oncology Conference, Olalekan Oluwole, MBBS, MPH, discusses some of the challenges he has encountered with chimeric antigen receptor T-cell therapy.

Ghassan Abou-Alfa, MD, discusses the approved agents available for the treatment of hepatocellular carcinoma. Compared to 2007 when there was only 1 agent available, sorafenib, there is now a great number of options for these patients.

Maurie Markman, MD, president of Medicine and Science, Cancer Treatment Centers of America, discusses how the ovarian cancer treatment paradigm has evolved over the past 30 years.

Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.

Sarah Holstein, MD, PhD, explains her rationale for choosing a triplet regimen over a quadruplet in patients with multiple myeloma.&nbsp;

Amol K. Narang, MD, discusses the improvement in systemic therapy for treatment of pancreatic cancer in recent years. He says that the combination of various chemotherapies are showing potential in a number of trials.

Stephanie K. Dougan, MD, assistant professor, Dana-Farber Cancer Institute and Harvard Medical School, discusses the idea of augmenting T cell immunity in tumors that are poorly immunogenic, such as pancreatic cancer.

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to TKIs in oncogene-driven non&ndash;small cell lung cancer.

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.

Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.